ClinicalTrials.gg
Active, not recruitingNCT05843643SELECT-SLEUpdated Apr 28, 2026

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

A Phase 3 interventional study of Upadacitinib and Placebo in Systemic Lupus Erythematosus, sponsored by AbbVie. Active, not recruiting at 369 sites in 38 countries. Open to participants aged 18 Years to 63 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,014
Allocation
Randomized
Ages
18 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
8th of 407
1,014 · median 70
Started
2023
with 22 others
Phase 3
70 of 477
14 open now
Primary completion
2027-03
later than 33 of 125 live
Registered
376th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 8th largest by enrollment of the 407 interventional ones that give a count, is one of 23 that started in 2023, is one of 70 in phase 3, reaches primary completion later than 33 of the 125 other live ones, and was the 376th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 63 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.

Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world.

Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • SLE
  • Upadacitinib
  • Lupus
04

Who can participate

Ages eligible
18 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of systemic lupus erythematosus (SLE) at least 24 weeks prior to screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)/ American College of Rheumatology (ACR) classification criteria for SLE.
  • At Screening, must have at least one of the following:

    • antinuclear antibody (ANA) positive (titer >= 1:80)
    • anti-double stranded deoxyribonucleic acid (dsDNA) positive
    • anti-Smith positive
  • Hybrid systemic lupus erythematosus disease activity index (hSLEDAI) >= 6, of which >= 4 points are clinical (not based on laboratory criteria), independently reviewed by the MCDR at Screening. Clinical hSLEDAI score (not based on laboratory criteria) must be re-confirmed as >= 4 at the Baseline visit. Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility but should be documented on the hSLEDAI if present.
  • Physician's Global Assessment (PhGA) >= 1 during screening period.
  • On stable background treatment for >= 60 days prior to Baseline (with the exception of oral [OCS], which must be at a stable dose for >=14 days prior to Baseline) with

    • antimalarial(s) [hydroxychloroquine \<= 400 mg daily, chloroquine \<= 500 mg daily, quinacrine \<= 100 mg daily];
    • and/or prednisone (or prednisone-equivalent) (\<= 20 mg daily);
    • and/or no more than 1 of the following: azathioprine (\<= 150 mg daily), 6-mercaptopurine (\<= 150 mg daily), mycophenolate mofetil (\<= 2 g daily), mycophenolate sodium \<= 1,440 mg/day, leflunomide (\<= 20 mg daily), cyclosporine, tacrolimus, voclosporin (\<= 23.7 mg twice daily), methotrexate (\<= 25 mg weekly), or mizoribine (\<= 150 mg daily).

Exclusion criteria

Exclusion Criteria:

  • Class III/IV lupus nephritis that was treated with induction therapy within the 6 months prior to Screening.
  • Active neuropsychiatric SLE (excluding lupus headache) within the 6 months prior to Screening.
  • SLE overlap syndromes including, but not limited to, rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, or mixed connective tissue disease (Sjögren's syndrome is permitted).
  • Antiphospholipid syndrome and prior unprovoked venous or arterial thrombosis who are not on stable and adequate anticoagulation.
  • Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster or herpes zoster ophthalmicus.
  • History of , except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
  • Pregnancy, breastfeeding, or considering becoming pregnant during the study.
  • or significant abnormalities at Screening.
  • Planned elective surgery that would impact study procedures or assessments through the completion of the Week 52 assessments.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,014 participants (actual)

Study arms

  • Experimental
    Study 1- Upadacitinib Dose A

    Participants will receive upadacitinib dose A once daily for 52 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Study 1- Placebo

    Participants will receive upadacitinib matching placebo once daily for 52 weeks.

    Drug: Placebo

  • Experimental
    Study 2- Upadacitinib Dose A

    Participants will receive upadacitinib dose A once daily for 52 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Study 2- Placebo

    Participants will receive upadacitinib matching placebo once daily for 52 weeks.

    Drug: Placebo

  • Experimental
    Study 3- Low Disease Activity Upadacitinib (LDA) Dose A

    Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose A once daily for 52 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3- Low Disease Activity Upadacitinib Dose B

    Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose B once daily for 52 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3- No LDA Upadacitinib Dose A

    Participants in the upadacitinib arms from Study 1 or Study 2 with no LDA will receive upadacitinib dose A once daily for 52 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3- Upadacitininb Dose A

    Participants in the placebo arms of Study 1 or Study 2 will receive upadacitinib Dose A once daily for 52 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 3- Open Label Upadacitinib Dose A

    Participants who experience a suspected systemic lupus erythematosus (SLE) flare may receive open label upadacitinib Dose A once daily for the remainder of the study.

    Drug: Upadacitinib

  • Experimental
    Study 3- Open Label Upadacitinib Dose B

    Participants who reach \>= 65 years of age and are still on study drug may receive open-label upadacitinib Dose B once daily, and participants who experience a suspected SLE flare while on upadacitinib Dose B may receive upadacitinib Dose A for the remainder of the study.

    Drug: Upadacitinib

  • Experimental
    Study 4- Upadacitinib Dose A

    Participants receiving upadacitinib Dose A in Study 3 will continue on this dose once daily for 104 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 4- Upadacitinib Dose B

    Participants receiving upadacitinib Dose B in Study 3 will continue on this dose once daily for 104 weeks.

    Drug: Upadacitinib

Interventions

  • Oral Tablets

    Also known as: RINVOQ

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving British Isles Lupus Assessment Group Based Combined Lupus Assessment (BICLA) Response

    BICLA is a composite responder index based on improvement in organ systems without worsening of the overall condition and improvement in disease activity.

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Flares Participants Experiencing Over Time.

    Flare is defined by the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) Systemic lupus erythematosus disease activity index (SLEDAI) Flare Index (SFI). An index defining Systemic lupus erythematosus (SLE) flares using changes in the Hybrid SLEDAI (hSLEDAI) score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity. Flare rate is number of flares per patient-year.

    Time frame: Week 52

  2. Percentage of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI) -4

    SRI is a composite responder index based on improvement in disease activity (number following SRI indicates numerical improvement in hSLEDAI score) without worsening of the overall condition (no worsening in Physician's Global Assessment (PhGA), \< 0.3 point increase) or the development of significant disease activity in new organ systems (no new British Isles Lupus Assessment Group \[BILAG\] A or \> 1 new BILAG B).

    Time frame: At Week 52

  3. Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS)

    LLDAS is a state of low disease activity based on SLEDAI score (hSLEDAI score \<= 4 excluding hSLEDAI activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA \<= 1), and concomitant medication usage.

    Time frame: At Week 52

  4. Time to First Flare per SELENA SLEDAI Flare Index (SFI)

    SFI is an index defining SLE flares using changes in the hSLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.

    Time frame: Week 52

  5. Percentage of Participants Achieving Oral Glucocorticoid Dose <=7.5 mg/day Prednisone-Equivalent

    Achievement of oral glucocorticoid dose \<=7.5 mg/day prednisone-equivalent among participants taking \>= 10 mg/day prednisone-equivalent at baseline.

    Time frame: From Week 44 to Week 52

  6. Percentage of Participants Achieving >= 50% Improvement in Tender or Swollen Joints

    Achievement of \>= 50% improvement in tender or swollen joints among participants with \>= 3 swollen joints and \>= 6 total affected joints at Baseline.

    Time frame: Week 52

  7. Percentage of Participants Achieving >= 50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score

    CLASI index used to assess cutaneous manifestations of SLE summarizing the activity of the disease. Scores range from 0 to 70, with higher scores indicating more severity. Achievement of \>= 50% reduction in CLASI activity score among participants with baseline score \>=10.

    Time frame: Week 52

  8. Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Version 4

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants. Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue.

    Time frame: Baseline to Week 52

  9. Change from Baseline in Lupus Pain Numerical Rating Scale (NRS)

    The Lupus Pain-NRS is a single-item questionnaire in which participants are asked to rate their overall pain level due to lupus over the last week. The Lupus Pain-NRS scores range from 0 to 10, with higher scores indicating a higher level of pain.

    Time frame: At Week 52

  10. Change from Baseline in 36-Item Short Form Health Survey (SF-36) Acute Physical Component Summary (PCS)

    The SF-36v2® Health Survey Acute is a general HRQoL instrument with extensive use in multiple disease states. The instrument comprises 36 total items (questions) targeting a participants's functional health and well-being in 8 dimensions (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Scoring is totaled into a Physical Component Summary and a Mental Component Summary. Higher scores indicate a better state of health.

    Time frame: Baseline to Week 52

07

Study locations

369 sites

Showing the first 100 of 369 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Jul 25, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843643
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jul 25, 2023
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion